Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional Accepts healthy volunteers

Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59

ClinicalTrials.gov ID: NCT00912496

Public ClinicalTrials.gov record NCT00912496. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase I Randomized Study of the Safety, Dose Escalation, and Immunogenicity of Adjuvanted Influenza A/Anhui/05 Boosting in Subjects Previously Immunized With One or Two Doses of A/Vietnam/1203/04 or in Unprimed Individuals and Compared to Placebo

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This research will study safety and the body's immune (defense system) responses, including anti-H5 flu antibodies (the body's protective proteins found in the blood), to an inactivated influenza "H5" bird flu, virus vaccine. Participants will be assigned by chance to receive the vaccine injections with and without an adjuvant, (substance that can improve vaccine effectiveness so less vaccine may be used) MF59, or placebo (inactive substance). Five different vaccine dose strengths will be evaluated. About 735 healthy participants, ages 18-49 will be asked to take part in this study. Study procedures include physical exam, blood sampling, and use of a memory aid. Volunteers will participate for up to 13 months.

Study identification

NCT ID
NCT00912496
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Enrollment
637 participants

Conditions and interventions

Conditions

Interventions

Biological · Drug

Eligibility (public fields only)

Age range
18 Years to 49 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2010
Primary completion
Nov 30, 2011
Completion
Nov 30, 2011
Last update posted
May 13, 2013

2010 – 2011

United States locations

U.S. sites
10
U.S. states
9
U.S. cities
9
Facility City State ZIP Site status
Emory Children's Center - Pediatric Infectious Diseases Atlanta Georgia 30322-1014
Emory University School of Medicine - Emory Children's Center - Pediatric Infectious Diseases Atlanta Georgia 30322
University of Iowa - Infectious Disease Clinic Iowa City Iowa 52242-1009
University of Maryland School of Medicine - Center for Vaccine Development - Baltimore Baltimore Maryland 21201-1509
Mayo Clinic, Rochester - Vaccine Research Group Rochester Minnesota 55905-0001
Saint Louis University - Center for Vaccine Development St Louis Missouri 63104-1015
Duke Translational Medicine Institute - Clinical Vaccine Unit Durham North Carolina 27704
Vanderbilt University - Pediatric - Infectious Diseases Nashville Tennessee 37232
University of Texas Medical Branch - Pediatrics - Infectious Diseases and Immunology - Galveston Galveston Texas 77555
Group Health Research Institute - Seattle Seattle Washington 98101

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00912496, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 13, 2013 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00912496 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →